Wegovy vs Mounjaro: Weight-Loss Approval vs Off-Label Use
Medically reviewed by Medical Advisory Board Last reviewed 2026-07-20
One is FDA-approved specifically for weight loss; the other produces more weight loss but for a different approved use
Wegovy (semaglutide) is FDA-approved specifically for chronic weight management. Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes and is prescribed for weight loss off-label, though its on-label sibling drug Zepbound carries the same molecule with the obesity indication. Trial data shows tirzepatide produces more average weight loss, but Wegovy has the longer track record and more consistent insurance framing for weight-loss use.
This article is for informational purposes only and is not medical advice. Consult a physician before starting, stopping, or switching any prescription medication.
Wegovy and Mounjaro are often searched together because both are once-weekly injections used for weight loss — but they carry different FDA approvals. Wegovy (semaglutide) is approved specifically for chronic weight management in adults with obesity or overweight plus a weight-related condition. Mounjaro (tirzepatide) is approved for type 2 diabetes; its identical molecule is sold as Zepbound when prescribed for weight loss. Many clinicians still prescribe Mounjaro off-label for weight loss, which is why the two get compared directly.
Want expert help with your metabolic health?
We can match you with a metabolic-medicine specialist who understands this area — so you get the right doctor, not just any doctor.
Book An Appointment With A Specialist →For the on-label weight-loss comparison of the same two molecules, see our Wegovy vs Zepbound guide. For the diabetes-label comparison, see Ozempic vs Mounjaro.
Wegovy vs Mounjaro at a Glance
Both are weekly injections that reduce appetite, but they work through different receptor mechanisms and carry different approvals. The table below compares them as they stand in 2026.| Factor | Wegovy (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| FDA approval | Chronic weight management | Type 2 diabetes (weight loss is off-label; see Zepbound) |
| Dosing | 0.25-2.4 mg weekly injection | 2.5-15 mg weekly injection |
| Average weight loss (trials) | ~14.9% body weight at 68 weeks (STEP-1) | ~20.9% body weight at 72 weeks (SURMOUNT-1, off-label weight-loss trial) |
| Insurance framing | Billed under the weight-loss indication directly | Often billed under diabetes coding; off-label weight-loss use complicates coverage |
| GI side effects | Nausea, vomiting, diarrhea during titration | Similar; possibly higher early nausea from the added GIP mechanism |
| Cost (without coverage) | ~$1,300-$1,400/month | ~$1,000-$1,100/month |
Why the Approval Difference Matters
Wegovy's specific weight-management approval means prescribers and insurers have a clear, on-label pathway for weight-loss use, with prior-authorization criteria built around that indication. Mounjaro's diabetes-only approval means a clinician prescribing it purely for weight loss is doing so off-label — legal and common in practice, but it can complicate insurance coverage, since many plans require a diabetes diagnosis to approve tirzepatide.
If weight loss is the sole goal and insurance coverage matters, Zepbound (tirzepatide's on-label weight-loss brand) is usually the more insurance-friendly way to access the same molecule as Mounjaro. See our Mounjaro vs Zepbound comparison for how the two differ despite being the same drug.
Which Produces More Weight Loss?
Trial data favors tirzepatide. The SURMOUNT-1 trial recorded average weight loss of about 20.9% of body weight at 72 weeks on the highest tirzepatide dose, compared with about 14.9% for semaglutide 2.4 mg in the STEP-1 trial. These were separate trials rather than a true head-to-head, but a 2024 real-world study (JAMA) comparing the two drugs directly found statistically significant greater weight loss with tirzepatide at one year.
The dual GIP/GLP-1 mechanism appears to explain the gap: GIP receptor activation seems to amplify GLP-1's appetite-suppressing effect and improve fat metabolism. See our GLP-1 peptides guide for how the mechanisms compare across the whole drug class.
Side Effects and Safety
Both drugs share the same core gastrointestinal side effects — nausea, vomiting, diarrhea, and constipation — most prominent during dose escalation and typically improving over the first 4-8 weeks. Both carry an FDA black-box warning about thyroid C-cell tumors based on rodent data, with unclear clinical significance in humans. Neither should be used during pregnancy.
Tirzepatide's added GIP mechanism may produce slightly higher early nausea rates for some patients during initial titration, though individual response varies considerably. A slow, physician-guided titration schedule reduces GI side effects for both drugs.
The Verdict: Which Should You Choose?
The choice usually comes down to insurance access and how much weight loss you need, not pure preference:
- Clear on-label weight-loss coverage matters: Wegovy, which is specifically approved and coded for chronic weight management.
- Maximizing average weight loss is the priority: tirzepatide (Mounjaro off-label, or Zepbound on-label) has the stronger trial numbers.
- You also have type 2 diabetes: Mounjaro directly targets both blood sugar and weight under one on-label prescription.
- You want the tirzepatide molecule with cleaner insurance framing for weight loss: ask about Zepbound instead of off-label Mounjaro.
A clinician who knows your full history and insurance situation is the right person to make this call. Take the free assessment to see whether insulin resistance or another metabolic factor should shape your plan before you compare specific drugs with your doctor.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.
Frequently Asked Questions
Is Mounjaro or Wegovy better for weight loss?
Clinical trial data favors tirzepatide (Mounjaro's molecule): the SURMOUNT-1 trial showed about 20.9% average body-weight loss at 72 weeks versus about 14.9% for semaglutide (Wegovy's molecule) in the STEP-1 trial, and a 2024 real-world study found tirzepatide produced significantly more weight loss at one year. Wegovy still has the more specific, longer-established weight-loss approval.
Can I get Mounjaro prescribed for weight loss instead of Wegovy?
Yes, but it would be off-label, since Mounjaro is FDA-approved for type 2 diabetes, not weight loss. Many clinicians do prescribe it off-label for weight loss, but insurance coverage is often easier for Wegovy (on-label for weight management) or Zepbound (tirzepatide's on-label weight-loss brand).
What is the difference between Mounjaro and Zepbound if I want weight loss?
They are the same drug, tirzepatide, sold under two brand names for two different FDA-approved uses: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. If weight loss is your only goal, Zepbound typically has a clearer path to insurance coverage than off-label Mounjaro.
Are Wegovy and Mounjaro covered by insurance?
Coverage varies significantly by plan. Wegovy is billed directly under its weight-management approval, which some plans cover and others exclude entirely. Mounjaro is typically billed under a diabetes diagnosis; using it off-label for weight loss without that diagnosis often means paying out of pocket or seeking Zepbound instead. Always verify your plan's prior-authorization requirements before starting.
What are the side effects of Wegovy vs Mounjaro?
Both cause similar gastrointestinal side effects — nausea, vomiting, diarrhea, and constipation — most common during dose escalation and easing over the first several weeks. Both carry a black-box warning about thyroid C-cell tumors based on rodent data. Tirzepatide's added GIP mechanism may cause slightly more early nausea for some patients.
Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Continue Reading
-
What Is Insulin Resistance? Causes, Symptoms & How to Reverse It
What insulin resistance is, how to test for it, and how to reverse it.
-
Hyperinsulinemia
Chronically high insulin: symptoms, causes, how it differs from insulin resistance, and how to reverse it.
-
Metabolic Syndrome — Diagnosis, Risks, and Treatment
The five diagnostic criteria and what they mean for your health.
-
Insulin Resistance Symptoms: 12 Warning Signs
12 clinical warning signs, from acanthosis nigricans to post-meal fatigue.
-
Blood Sugar Crash: Why It Happens and How to Stop It
Reactive hypoglycemia: causes, symptoms, and how to stabilize glucose.
-
Glucose Spikes After Eating: Causes and What to Do
Why blood sugar spikes after eating and what to do about it.
-
Fatigue After Eating: Why Food Makes You Tired
Post-meal fatigue explained — insulin, glucose, and the gut-brain axis.
-
Hypoglycemia Symptoms: Low Blood Sugar Warning Signs
Low blood sugar warning signs and when to seek medical attention.
-
How to Reverse Insulin Resistance Naturally
Evidence-based dietary and lifestyle interventions (3-16 week timeline).
-
Slow Metabolism: Myths, Causes, and What Actually Works
Why metabolism slows, what's myth vs reality, and what the evidence says.
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. As an Amazon Associate we earn from qualifying purchases. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.